WO2001007022A3 - Azetidine compounds in cns and eye diseases - Google Patents

Azetidine compounds in cns and eye diseases Download PDF

Info

Publication number
WO2001007022A3
WO2001007022A3 PCT/GB2000/002817 GB0002817W WO0107022A3 WO 2001007022 A3 WO2001007022 A3 WO 2001007022A3 GB 0002817 W GB0002817 W GB 0002817W WO 0107022 A3 WO0107022 A3 WO 0107022A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye diseases
cns
azetidine compounds
azetidine
compounds
Prior art date
Application number
PCT/GB2000/002817
Other languages
French (fr)
Other versions
WO2001007022A2 (en
Inventor
Mike Frederick Snape
Original Assignee
Vernalis Res Ltd
Mike Frederick Snape
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd, Mike Frederick Snape filed Critical Vernalis Res Ltd
Priority to AU60060/00A priority Critical patent/AU6006000A/en
Priority to EP00946187A priority patent/EP1196165A2/en
Priority to JP2001511908A priority patent/JP2003505413A/en
Publication of WO2001007022A2 publication Critical patent/WO2001007022A2/en
Publication of WO2001007022A3 publication Critical patent/WO2001007022A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Use of a compound of formula (I) wherein R1 is aryl; and R2 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.
PCT/GB2000/002817 1999-07-23 2000-07-21 Azetidine compounds in cns and eye diseases WO2001007022A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU60060/00A AU6006000A (en) 1999-07-23 2000-07-21 Chemical compounds-iii
EP00946187A EP1196165A2 (en) 1999-07-23 2000-07-21 Azetidine compounds in cns and eye diseases
JP2001511908A JP2003505413A (en) 1999-07-23 2000-07-21 Azetidine compounds in the CNS and eye diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9917384.1A GB9917384D0 (en) 1999-07-23 1999-07-23 Chemical compounds-III
GB9917384.1 1999-07-23

Publications (2)

Publication Number Publication Date
WO2001007022A2 WO2001007022A2 (en) 2001-02-01
WO2001007022A3 true WO2001007022A3 (en) 2001-06-14

Family

ID=10857862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002817 WO2001007022A2 (en) 1999-07-23 2000-07-21 Azetidine compounds in cns and eye diseases

Country Status (5)

Country Link
EP (1) EP1196165A2 (en)
JP (1) JP2003505413A (en)
AU (1) AU6006000A (en)
GB (1) GB9917384D0 (en)
WO (1) WO2001007022A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367785B1 (en) * 2008-11-24 2014-10-15 Integrative Research Laboratories Sweden AB Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872447A (en) * 1958-12-23 1961-07-12 Lepetit Spa 1-carbamyl-3-substituted azetidines
WO1999037613A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872447A (en) * 1958-12-23 1961-07-12 Lepetit Spa 1-carbamyl-3-substituted azetidines
WO1999037613A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 55, no. 23, 1961, Columbus, Ohio, US; abstract no. 23481e, column 23481; XP002162437 *
TESTA E. ET AL.: "Substances acting on the central nervous system. XV-III. 3-Phenylazetidine", ANN., vol. 639, 1961, pages 157 - 165 *

Also Published As

Publication number Publication date
EP1196165A2 (en) 2002-04-17
GB9917384D0 (en) 1999-09-22
WO2001007022A2 (en) 2001-02-01
AU6006000A (en) 2001-02-13
JP2003505413A (en) 2003-02-12

Similar Documents

Publication Publication Date Title
TWI255807B (en) Therapeutic agents
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
DE60329001D1 (en) 8-hydroxychinolinderivate
NO20055655L (en) Use of azetidinecarboxamide derivatives in therapy
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
WO2004013120A8 (en) Novel benzodioxoles
WO2002008219A3 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
CA2243234A1 (en) 5h-thiazolo[3,2-a]pyrimidine derivatives
AU5752194A (en) Benzimidazole compounds, their use and preparation
ZA200501098B (en) Novel use of benzothiazole derivatives
MXPA05011207A (en) Use of derivatives of 2, 4-dihydro-[1,2,4]triazole-3-thione as inhibitors o fteh enzyme myeloperoxidase (mpo).
EP1142881A4 (en) Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
WO2001007023A3 (en) Azetidine compounds in cns and eye diseases
EP1557414A4 (en) Isoquinoline compounds and medicinal use thereof
WO2001007022A3 (en) Azetidine compounds in cns and eye diseases
MXPA04005077A (en) Benzothiazole derivatives.
WO2005053702A3 (en) Anti-inflammatory agents
IL125591A0 (en) 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor antagonists
WO1999038841A8 (en) Adamantanecarboximidamide derivatives and their use as nmda antagonists
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
AU2116900A (en) 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000946187

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000946187

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10031708

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000946187

Country of ref document: EP